Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce L Innis

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
The New England Journal of Medicine|January 6, 2006
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritisGuillermo M Ruiz-Palacios, Irene Pérez-Schael, F Raúl Velázquez, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
The Pediatric Infectious Disease Journal|July 16, 2019
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza VaccineJasur Danier, Luis Rivera, Carine Claeys, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
The Pediatric Infectious Disease Journal|November 15, 2019
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical TrialGhassan Dbaibo, Arshad Amanullah, Carine Claeys, et al.
The Lancet. Child & Adolescent Health|September 1, 2018
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasonsCarine Claeys, Khalequ Zaman, Ghassan Dbaibo, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
The New England Journal of Medicine|January 6, 2006
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritisGuillermo M Ruiz-Palacios, Irene Pérez-Schael, F Raúl Velázquez, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
The Pediatric Infectious Disease Journal|July 16, 2019
Clinical Presentation of Influenza in Children 6 to 35 Months of Age: Findings From a Randomized Clinical Trial of Inactivated Quadrivalent Influenza VaccineJasur Danier, Luis Rivera, Carine Claeys, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
The Pediatric Infectious Disease Journal|November 15, 2019
Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical TrialGhassan Dbaibo, Arshad Amanullah, Carine Claeys, et al.
The Lancet. Child & Adolescent Health|September 1, 2018
Prevention of vaccine-matched and mismatched influenza in children aged 6-35 months: a multinational randomised trial across five influenza seasonsCarine Claeys, Khalequ Zaman, Ghassan Dbaibo, et al.
Pageof 12